{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Olson AP"],"funding":["Office of Isotope Research and Development and Production","Workforce Development for Teachers and Scientists","National Cancer Institute","NCI NIH HHS","National Institutes of Health","Office of Isotope R and D and Production","NIH HHS"],"pagination":["e202423878"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12536330"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["64(15)"],"pubmed_abstract":["Antimony-119 (<sup>119</sup>Sb) is one of the most attractive Auger-electron emitters identified to date, but it remains practically unexplored for targeted radiotherapy because no chelators have been identified to stably bind this metalloid in vivo. In a departure from current studies focused on chelator development for Sb(III), we explore the chelation chemistry of Sb(V) using the tris-catecholate ligand TREN-CAM. Through a combination of radiolabeling, spectroscopic, solid-state, and computational studies, the radiochemistry and structural chemistry of TREN-CAM with <sup>1XX/nat</sup>Sb(V) were established. The resulting [<sup>1XX</sup>Sb]Sb-TREN-CAM complex remained intact for several days in human serum, signifying high stability under biological conditions. Finally, the first in vivo"],"journal":["Angewandte Chemie (International ed. in English)"],"pubmed_title":["Towards the Stable Chelation of Radioantimony(V) for Targeted Auger Theranostics."],"pmcid":["PMC12536330"],"funding_grant_id":["F31 CA239617","F31CA239617","P01CA250972","P01 CA250972"],"pubmed_authors":["Ivanov AS","Dierolf MA","Driscoll DM","Kertesz V","Verich F","Schrage BR","Becker KV","Fletcher LS","Boros E","Olson AP","Engle JW","White FD","Girish N","Thiele NA","Islam MF","Aluicio-Sarduy E","Simms ME"],"additional_accession":[]},"is_claimable":false,"name":"Towards the Stable Chelation of Radioantimony(V) for Targeted Auger Theranostics.","description":"Antimony-119 (<sup>119</sup>Sb) is one of the most attractive Auger-electron emitters identified to date, but it remains practically unexplored for targeted radiotherapy because no chelators have been identified to stably bind this metalloid in vivo. In a departure from current studies focused on chelator development for Sb(III), we explore the chelation chemistry of Sb(V) using the tris-catecholate ligand TREN-CAM. Through a combination of radiolabeling, spectroscopic, solid-state, and computational studies, the radiochemistry and structural chemistry of TREN-CAM with <sup>1XX/nat</sup>Sb(V) were established. The resulting [<sup>1XX</sup>Sb]Sb-TREN-CAM complex remained intact for several days in human serum, signifying high stability under biological conditions. Finally, the first in vivo","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-04T14:14:44.863Z","creation":"2026-05-10T03:11:33.569Z"},"accession":"S-EPMC12536330","cross_references":{"pubmed":["39878457"],"doi":["10.1002/anie.202423878"]}}